TITLE

Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy

AUTHOR(S)
Takano, Masamichi; Yamamoto, Masanori; Yong Xie; Murakami, Daisuke; Inami, Shigenobu; Okamatsu, Kentaro; Seimiya, Koji; Ohba, Takayoshi; Seino, Yoshihiko; Mizuno, Kyoichi
PUB. DATE
November 2007
SOURCE
Heart;Nov2007, Vol. 93 Issue 11, p1353
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: Progression of neointimal stent coverage (NSC) and changes in thrombus were evaluated serially by coronary angioscopy for up to 2 years after sirolimus-eluting sterit (SES) implantation. Methods: Serial angioscopic observations were performed in 20 segments of 20 patients at baseline, at 6 months and at 2 years after SES implantation. NSC was classified as follows: 0, uncovered struts; 1, visible struts through thin rieointima; or 2, no visible struts. In each patient, maximum and minimum NSC was evaluated. Existence of thrombus was also examined. Results: The maximum NSC increased from 6 months to 2 years (mean (SD) 1.2 (0.4) vs 1.8 (0.4), respectively, p=0.005), while the minimum NSC did not change (0.7 (0.5) vs 0.8 (0.4), respectively, p = 0.25). The prevalence of patients with uncovered struts did not decrease from 6 months to 2 years (35% vs 20%, respectively, p=0.29). Although there were no thrombus-related adverse events, new thrombus formation was found in 5% of 6-month, and in 20% of 2-year follow-up evaluations. The prevalence of thrombus inside the SES at baseline, 6 months and 2 years was similar (40%, 40% and 30%, respectively; p=NS). Conclusions: Neointimal growth inside the SES progressed heterogeneously. Uncovered struts persisted in 20% of the patients for up to 2 years and subclinical thrombus formation was not uncommon.
ACCESSION #
27441256

 

Related Articles

  • Comparison of axial force and cell width of self-expandable metallic stents: which type of stent is better suited for hilar biliary strictures? Mukai, Tsuyoshi; Yasuda, Ichiro; Isayama, Hiroyuki; Nakashima, Masanori; Doi, Shinpei; Iwashita, Takuji; Iwata, Keisuke; Kato, Tomohiro; Tomita, Eiichi; Moriwaki, Hisataka // Journal of Hepato -- Biliary -- Pancreatic Sciences;Sep2011, Vol. 18 Issue 5, p646 

    Background: Various types of self-expandable metallic stents (SEMSs) are commercially available. However, few reports have compared the performance of the various SEMSs. In addition to long-term patency, maneuverability during initial placement and feasibility of re-intervention for the stent...

  • Drug-Eluting Intra-Coronary Stents: Have We Got the Magic Bullet? Bhatia, V.; Bhatia, R.; Dhindsa, S. // Journal of Postgraduate Medicine;Jul-Sep2003, Vol. 49 Issue 3, p291 

    Explores mechanisms of in-stent restenosis. Recurrence of restenosis in patients in whom restenosis occurs after coronary stenting; Discussion of the novel strategy of coating stents with anti-proliferative drugs to prevent the complication; Role of stent placement in de-endothelialization.

  • Stenting of residual hypoplastic aortic segments late after coarctectomy.  // Cardiology in the Young;May2005 Supplement 2, Vol. 15 Issue S2, p27 

    This article presents a study to assess the feasibility, efficacy and safety of stent expansion of residual hypoplastic segments late after coarctectomy. Residual hypoplasia of the aortic cross and isthmus may persist despite adequate coarctectomy; such hypoplasia creates a gradient,...

  • Serial long-term evaluation of neointimal stent coverage and thrombus alter sirolimus-eluting stent implantation by use of coronary angioscopy. Takano, Masamichi; Yamamoto, Masanor; Yong Xie; Murakami, Daisuke; Inami, Shigenobu; Okamatsu, Kentaro; Seimiya, Koli; Ohba, Takayoshi; Seino, Yoshihiko; Mizuno, Kyoichi // Heart;Dec2007, Vol. 93 Issue 12, p1533 

    Objective: Progression of neointimal stent coverage (NSC) and changes in thrombus were evaluated serially by coronary angioscopy for up to 2 years after sirolimus-eluting stent (SES) implantation. Design: Serial angioscopic observations were performed in 20 segments of 20 patients at baseline,...

  • BILIARY STENTS IN THE TREATMENT OF MALIGNANT DUCTAL OBSTRUCTION. Brandon, Jeffrey C.; Teplick, Steven K. // American Journal of Gastroenterology;Apr1996, Vol. 91 Issue 4, p627 

    Comments on a study which dealt with the use of endoscopic stent placement in patients with malignant biliary obstruction who were not candidates for surgical resection. Types of stents used; Popularity of palliative bile duct stenting for malignant bile duct obstruction; Implication of the...

  • Medical technology: a cost solution in drug elution?  // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p35 

    The article focuses on the cost effectiveness of using drug-eluting stents, rather than plain metal stents for acute heart attack patients. It reported that drug elution can be cost-effective as that of traditional stents when combined with anti-platelet regiments, a novel treatment strategy,...

  • TCT notebook.  // Medical Device Daily;10/25/2007, Vol. 11 Issue 205, p3 

    The article presents the four-month results for Excella, a first-in-man clinical trial of the Novolimus-eluting coronary stent, reported by Elixir Medical, a developer of drug-eluting stent platforms in Sunnyvale, California. Findings show that the Novolimus system was effective in reducing...

  • ISAR LEFT MAIN: Paclitaxel-eluting stent noninferior to sirolimus-eluting stent for unprotected left main disease.  // Cardiology Today;Dec2008, Vol. 11 Issue 12, p16 

    The article discusses the results of the ISAR LEFT MAIN trial, which suggested that paclitaxel-eluting stent was noninferior to the sirolimus-eluting stent in patients with unprotected left main coronary artery disease. Similar target lesion revascularization between those receiving the...

  • Cappella Medical Announces Excellent Long Term Follow-Up Clinical Data on Its Sideguard Technology.  // Biomedical Market Newsletter;10/17/2011, Vol. 21, p560 

    The article reports on the initial long term follow up data available for Sideguard (r) coronary sidebranch stent manufactured by Cappella Medical Devices Ltd. (Cappella) in Ireland. It notes that the data was obtained from patients who received the Sideguard which was developed to protect the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics